French multicentre observational study on SARS-CoV-2 infections intensive care initial management: the FRENCH CORONA study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roger Claire, Collange Olivier, Mezzarobba Myriam, Abou-Arab Osama, Teule Lauranne, Garnier Marc, Hoffmann Clément, Muller Laurent, Lefrant Jean-Yves, Guinot Pierre Grégoire, Novy Emmanuel, Abraham Paul, Clavier Thomas, Bourenne Jérémy, Besch Guillaume, Favier Laurent, Fiani Michel, Ouattara Alexandre, Joannes-Boyau Olivier, Fischer Marc-Olivier, Leone Marc, Ait Tamlihat Younes, Pottecher Julien, Cordier Pierre-Yves, Aussant Philippe, Moussa Mouhamed Djahoum, Hautin Etienne, Bouex Marine, Julia Jean-Michel, Cady Julien, Danguy Des Déserts Marc, Mayeur Nicolas, Mura Thibault, Allaouchiche Bernard, AZUREA group
Аннотация
METHODS: Prospective multicentre, cohort study conducted in 29 French ICUs. Baseline characteristics, comorbidities, adjunctive therapies, ventilatory support at ICU admission and survival data were collected.
RESULTS: From March to July 2020, 966 patients were enrolled with a median age of 66 (interquartile range 58-73) years and a median SAPS II of 37 (29-48). During the first 24 h of ICU admission, COVID-19 patients received one of the following respiratory supports: mechanical ventilation for 559 (58%), standard oxygen therapy for 228 (24%) and high-flow nasal cannula (HFNC) for 179 (19%) patients. Overall, 721 (75%) patients were mechanically ventilated during their ICU stay. Prone positioning and neuromuscular blocking agents were used in 494 (51%) and 460 (48%) patients, respectively. Bacterial co-infections and ventilator-associated pneumonia were diagnosed in 79 (3%) and 411 (43%) patients, respectively. The overall 28-day mortality was 18%. Age, pre-existing comorbidities, severity of respiratory failure and the absence of antiviral therapy on admission were identified as independent predictors of 28-day outcome.
CONCLUSION: Severity of hypoxaemia on admission, older age (> 70 years), cardiovascular and renal comorbidities were associated with worse outcome in COVID-19 patients. Antiviral treatment on admission was identified as a protective factor for 28-day mortality. Ascertaining the outcomes of critically ill COVID-19 patients is crucial to optimise hospital and ICU resources and provide the appropriate intensity level of care.